FDA’s elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS Therapies on track to complete clinical data submission by the end of Q1 2026 New York, New York–(Newsfile Corp. – March 9, 2026) – OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), …
Read More »
Matribhumi Samachar English